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study. Further study is warranted for a causal link between general
sickness and speciﬁc cytokines during human GVHD develop-
ment.
Table 1. Correlations between Symptom Severity and IL-8 Levels
before and after the Development of GVHD in the First 100 Days
after Allo-BMT
Symptom Correlation with IL-8 Levels
Pre-GVHD
Shortness of breath r  0.708, P < .01
Dry mouth r  0.667, P < .05
Sadness r  0.631, P < .05
Post-GVHD
Sleep disturbance r  0.564, P < .05
Drowsiness r  0.565, P < .05
Vomiting r  0.558, P < .05
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INCREASED CLEARANCE OF ASPERGILLUS FUMIGATUS IN MICE WITH
CHRONIC LUNG INJURY AFTER ALLOGENEIC STEM CELL TRANSPLAN-
TATION
Hildebrandt, G.C.1, Olkiewicz, K.2, Hogaboam, C.M.3, Ferrara, J.L.2,
Cooke, K.R.2 1Department of Hematology and Oncology, University of
Regensburg Medical School, Regensburg, Germany; 2Department of Pe-
diatrics, University of Michigan Medical School, Ann Arbor, MI; 3De-
partment of Pathology, University of Michigan Medical School, Ann
Arbor, MI.
Chronic lung injury (CLI) is a frequent problem after allogeneic
(allo) stem cell transplantation (SCT) leading to obstructive and/or
restrictive changes in lung function. CLI is associated with signif-
icant morbidity and mortality and is frequently complicated by
co-existing opportunistic infections. We developed a murine SCT
model of CLI by transplanting splenocytes and bone marrow cells
from G-CSF treated syngeneic (syn) B6D2F1 or allo C57BL/6
donor mice into lethally irradiated B6D2F1 recipients. Animals
were analyzed between day 90 and 100 after transplant. Allo but
not syn recipients showed typical changes of CLI: pulmonary
resistance was signiﬁcantly increased (146 12 vs. 106 5%), and
lung compliance was decreased (62  6 vs. 77  3%) compared to
syn controls (P  .01) Functional changes correlated with signiﬁ-
cant histopathology, including a dense mononuclear cell inﬁltrate
around bronchial structures (score: 5.3  0.7 vs. 0.3  0.3; P 
.01), peribronchial ﬁbrosis and pulmonary collagen deposition.
Histopathologic changes were associated with increased numbers
of BALF total cells (1.68  0.26 vs. 0.89  0.08  106; P  .01),
and both CD4 (2.9  0.4 vs. 1.4  0.1  105; P  .01) and
CD8 T cells (1.0  0.1 vs. 0.1  0.0  105; P  .01). Interest-
ingly, IFN- CD4 and IFN- CD8 T cells and lung mRNA
for CCR2 were also increased indicating a local proinﬂammatory
environment. Next we determined whether animals with CLI after
allo-SCT were more susceptible to fungal infection than syn con-
trols. SCT recipients were injected intratracheally with 5  106
Aspergillus fumigatus (A.f.) conidia around day 70 and were analyzed
3 weeks later. Surprisingly, recipients of allo-SCT showed in-
creased pulmonary clearance of A.f. with signiﬁcant reductions of
conidia within the bronchial epithelium and of associated goblet
cell hyperplasia compared to syn controls. Conclusion: Despite
the development of signiﬁcant CLI, allo-SCT recipients have en-
hanced clearance of A.f. conidia compared to syn controls. These
data suggest that the proinﬂammatory micro-environment associ-
ated with non-infectious lung injury after SCT may have a here-
tofore unidentiﬁed beneﬁcial effect on immune surveillance, per-
haps calling into question the merits of continuing systemic
immunosuppression in patients with CLI without evidence for
clear improvements in lung function.
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DONOR-SPECIFIC CELL ENGRAFTMENT AFTER INTRAOSSEOUS AND
INTRAVENOUS BONE MARROW TRANSPLANTATION
Klimczak, A.1, Unal, S.1, Jankowska, A.1, Coburn, C.1,
Siemionow, M.1 1The Cleveland Clinic Foundation, Cleveland, OH.
Background: Engraftment of donor-derived bone marrow cells
into recipient bone marrow environment can induce hematopoietic
chimerism and tolerance to antigen-matched organs in solid organ
and composite tissue allograft. This study was designed to inves-
tigate the effect of intraosseous bone marrow transplantation
(BMT) for donor cells engraftment into the bone marrow envi-
ronment and lymphoid tissue compartment across MHC barrier
under short-term 
-TCRmAb/CsA protocols. Materials and
Methods: Forty-eight BMT were performed between ACI (RT1a)
donors and LEW (RT1l) recipients. Intraosseous and intravenous
BMT was studied in 6 groups of 8 animals each receiving 35  106
(n  4) and 70  106 (n  4) bone marrow cells. Groups I and II
(controls) received BMT but no treatment, groups III and IV CsA
monotherapy, and groups V, VI 
-TCRmAb/CsA protocol for 7
days. Flow cytometry monitored immunodepletion and donor-
speciﬁc chimerism for MHC class I (RT1a) antigens in the periph-
eral blood and bone marrow compartment. Immunocytochemical
staining was employed to detect the presence of donor-derived
cells in the lymphoid tissue of recipients. Results: All animals
survived without the occurrence of graft versus host disease. Short
term 
-TCRmAb/CsA protocol and 70  106 bone marrow cells
delivery resulted in 7.9%  1.3% of donor cell engraftment after
intraosseous BMT compared to 4.2%  1.4% after intravenous
transplantation. Donor bone marrow cell engraftment into the
recipient bone marrow compartment delivered via the intraosseous
route under the 
-TCRmAb/CsA protocol was 40% more efﬁ-
cient after 70  106 bone marrow cell transplantation compared to
35  106 (7.9% vs 4.8% respectively). Also, CsA monotherapy and
70  106 bone marrow cell delivery resulted in better engraftment
of donor cells after intraosseous transplantation compared to 35 
106 of BMT (3.8% vs 2.2% respectively). Donor-derived cells were
present in the lymph nodes and spleen of recipients. Higher seed-
ing efﬁciency of donor cells into the lymphoid tissue compartment
was achieved after intraosseous BMT and 
-TCRmAb/CsA pro-
tocol compared to standard intravenous transplantation. Conclu-
sion: Intraosseous transplantation of donor bone marrow cells
under 
-TCRmAb/CsA protocol was more effective for donor
cell engraftment into recipients’ bone marrow environment and
lymphoid tissue compartment compared to intravenous transplan-
tation.
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ALLOGENEIC TRANSPLANTATION FOR ADULT ACUTE LYMPHOBLASTIC
LEUKEMIA: INTENTION TO TREAT ANALYSIS OF THE EORTC ALL-4
PHASE III TRIAL
Labar, B.1, Suciu, S.2, Muus, P.3, Willemze, R.4, Marie, J.-P.5,
Fillet, G.6, Berneman, Z.7, Jaksic, B.8, Feremans, W.9, Bron, D.10,
Sinnige, H.11, Mistrik, M.12, Vreugdenhil, G.13, De Bock, R.14,
Nemet, D.1, Gilotay, C.2, De Witte, T.3, Amadori, S.15 1University
Hospital Center Rebro, Zagreb, Croatia; 2EORTC Data Center, Brus-
sels, Belgium; 3St. Radboud University Hospital, Nijmegen, The Neth-
erlands; 4Leiden University Hospital, Leiden, The Netherlands; 5Hotel-
Dieu de Paris, Paris, France; 6CHU Sart-Tilman, Liege, Belgium;
7Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium; 8Clinical
Hospital Merkur, Zagreb, Croatia; 9Hopital Universitaire Erasme,
Brussels, Belgium; 10Institut Jules Bordet, Brussels, Belgium; 11Groot
Ziekengasthuis, Den Bosch, Netherlands; 12University Hospital,
Bratislava, Slovakia (Slovak Republic); 13St. Josef Ziekenhuis, Veld-
hoven, The Netherlands; 14Algemeen Ziekenhuis Middelheim, Antwer-
pen, Belgium; 15Ospedale San Eugenio, Rome, Italy.
Results of the EORTC ALL-3 reveal that the policy to perform
allo-SCT in a case when a sibling donor is available does not result
in a signiﬁcantly better outcome than to offer auto-SCT or con-
tinuous maintenance. We also analysed the outcome of allografted
patients in EORTC ALL-4. In this trial patients were randomized
to receive either dexamethasone (10 mg/m2/day) or 6-methyl-
prednisolone (60 mg/m2/day) on days 1-8 and 15-22 with standard
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induction chemotherapy (cyclophosphamide, daunorubicin, vin-
cristine and MTX i.t.). After induction all patients had to receive a
HAM consolidation course (HD-AraC 3 g/m2 every 12 hours, days
1-4; mitoxantrone 10 mg/m2, days 5-7 and MTX i.t.). Patients in
CR received two courses of MA consolidation (MTX 1.5 g/m2 day
1 and l-asparaginase 104 IU/m2 day 2), and then underwent allo-
SCT or patients without a donor were randomized either to re-
ceive autologous stem cells from peripheral blood or high main-
tenance therapy. The median follow-up was 4.9 years. Between
1998 and 2003, a total of 325 pts entered the study. The median
age was 32 yrs range 15-72 yrs. In 248 (76%) patients CR1 was
reached and 227 of them were HLA typed; 100 had an identical
sibling donor and 127 had no sibling donor. Allo-SCT was per-
formed in 69 (69%) pts and auto-SCT or high maintenance ther-
apy in 58 (46%). The 5-year DFS of pts with a donor vs pts without
a donor was 41.8% vs. 35.5% , P  .40, hazard ratio 0.86, 95% CI
0.61-1.22). The relapse incidence was signiﬁcantly lower (37.3%
vs. 58.8% P  .004) and treatment related mortality (TRM) was
signiﬁcantly higher (20.9% vs. 5.7%, P  .0005) in the donor
group compared to the no donor group. Five-year survival in pts
with and without the donor was 43.0% and 36.9% respectively. For
pts50 years of age 199 of them were HLA-typed; 91 had a donor
and 108 had no sibling donor. The 5-yr DFS rate in the donor vs
no donor group was 42.2% vs. 36.2%, P  .36, hazard ratio 0.84
95% CI 0.58-1.22). Relapse rate was signiﬁcantly lower and TRM
was signiﬁcantly higher in the donor versus no donor group.
Five-year survival for patients with and without a donor was 43.9%
and 37.4% respectively (P  .58), hazard ratio 0.90 (95% CI
0.61-1.32). In conclusion, in the EORTC ALL-4 trial, the inten-
tion to treat analysis shows that DFS and survival rate for al-
lografted pts younger than 50 years of age were not signiﬁcantly
different compared to those receiving auto-SCT or high mainte-
nance. High TRM (20%) remains the main problem of allograft-
ing.
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THE FEASIBILITY OF CONDITIONING REGIMEN OF FLUDARABINE, ATG,
AND REDUCED DOSE OF CYCLOPHOSPHAMIDE IN PATIENTS WITH
SEVERE APLASTIC ANEMIA WHO RECEIVED HLA-MATCHED SIBLING
TRANSPLANTATION
Lee, J.W.1, Kim, S.Y.1, Eom, K.S.1, Kim, Y.J.1, Kim, H.J.1,
Min, C.K.1, Lee, S.1, Cho, S.G.1, Min, W.S.1, Kim, C.C.1 1Catholic
Hematopoietic Stem Cell Transplantation Center, The Catholic Univer-
sity of Korea, Seoul, Korea.
Background: High dose (HD) cyclophosphamide (CY, 200 mg/
kg) plus ATG seems to be accepted as standard conditioning
regimen in HLA-matched sibling stem cell transplantation (SCT)
for severe aplastic anemia (SAA). However, HD CY causes serious
cardiac toxicity in some cases which may lead to death within a few
weeks. To avoid HD CY-associated cardiac toxicity we underwent
HLA-matched sibling SCT using ATG, reduced CY to half dose
with incorporation of ﬂudarabine. Methods: Between March 2002
and August 2005, consecutive twenty-six patients with adult SAA
(six patients were AA/PNH syndrome) received matched sibling
SCT. The median age of patients was 41 (21-52) and median
interval between Dx and SCT was 30 months (1-352). The median
number of transfusions prior to SCT was 34 units (4-680). Ten
patients (38%) had a history of IST before SCT. The conditioning
regimen consisted of ﬂudarabine (30 mg/m2/day, 6 days), cyclo-
phosphamide (50 mg/kg/day, 2 days) and ATG (2.5 mg/kg/day, 4
days, IMTIX-SangStat). Stem cell sources were BM plus CD34-
selected PBSC (n 9), BM (n 14), or PBSC (n 3). All patients
received of cyclosporine and methotrexate as GVHD prophylaxis.
Results: The median dose of CD34 cells infused was 3.6 
106/kg (1.2-11.9). All patients achieved successful sustained en-
graftment, and the median time for ANC and platelet to reach
0.5  109/L and 20  109/L was 12 (6-16) and 18 (10-23) days,
respectively. None of the patients developed cardiac toxicity or
regimen-related toxicities. One patient developed delayed graft
failure, but achieved successful engraftment after second SCT
using TNI  ATG. The incidence of acute GVHD (more than
grade II) was 8% (n 2) and none developed chronic GVHD. The
incidence of CMV infection requiring preemptive treatment was
38% (n  10). Only one patient died of hepatic failure due to
reactivation of chronic hepatitis C with hepatic GVHD posttrans-
plant 3 months. PNH clone measured by ﬂow cytometry disap-
peared posttransplant in 6 PNH patients. With median follow up
of 12 months (2-41), the estimated probability of survival at 2 years
was 96%. Conclusions: These data demonstrate that the condi-
tioning regimen used in this study is feasible for patients with SAA
who receive matched sibling SCT. Of note, the observations of
successful engraftment as well as lesser acute GVHD and no
chronic GVHD suggest that a ﬂudarabine-based regimen has more
potent immunomodulatory activity.
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RESPIRATORY VIRUS INFECTION AMONG HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) RECIPIENTS: QUANTITATIVE VIRAL LOAD
IN SYMPTOMATIC AND ASYMPTOMATIC INFECTIONS
Peck, A.J.1,2,3, Englund, J.A.1,2, Kuypers, J.1,2,3, Corey, L.2,3,
Morrow, R.1,2,3, Cent, A.1,2,3, Boeckh, M.2,3 1Children’s Hospital &
Regional Medical Center, Seattle, WA; 2University of Washington,
Seattle, WA; 3Fred Hutchinson Cancer Research Center, Seattle, WA.
Background: Inﬂuenza (ﬂu), respiratory syncytial virus (RSV), and
parainﬂuenza virus (PIV) may cause serious respiratory disease fol-
lowing HCT, with infection rates of 2-10%. The extent of infection
and disease due to human metapneumovirus (MPV) is largely un-
known. We assessed viral infectious episodes after HCT using con-
ventional and quantitative molecular detection. Methods: Weekly
symptom surveys, nasal washes and throat swabs were collected from
HCT recipients for 100 days post-HCT between Jan. 2001-June
2004. Samples were tested by culture and DFA for RSV, PIV and Flu,
and by RT-PCR for RSV, PIV, MPV, and ﬂu (detection limit 1100
copies/ml). Longitudinal analysis was performed for patients with5
serial samples or a positive test or death. Results:Of 119 patients, 29
had 31 (26%) separate infectious episodes due to RSV (5), PIV (16),
MPV (6), ﬂu (3), RSV and ﬂu (1). Median time to viral detection was
48 (range 3-96) days after HCT; median duration of viral shedding
was 14 (range 5-42) days in 19 evaluable episodes. Six patients with
PIV remained asymptomatic at the time of positivity, conventional
testing was negative in 5. No asymptomatic shedding of RSV, MPV
or ﬂu was found. PCR testing nearly doubled ﬁrst identiﬁcation of
RSV and PIV infectious episodes: 11 were detected by PCR plus
conventional methods (in 2 patients, PCR detection preceded con-
ventional methods) and 9 were detected by PCR alone. Median virus
copy number in samples from asymptomatic weeks (2.3 104 copies/
ml) differed from samples from symptomatic weeks (8.6 105 copies/
ml; P value .004). Similarly, viral load in samples from patients with 0
or 1 symptoms (2.4  104 copies/ml) was signiﬁcantly lower com-
pared with patients that reported 	1 symptom (1.8  106; P value
.001). PIV was the only virus that showed a lower viral load in patients
with 0 or 1 symptoms compared with 	1 (P value .04). Conclusion:
Both symptomatic and asymptomatic viral shedding among allogeneic
HCT recipients were detectable using virus-speciﬁc molecular test-
ing. Utilization of PCR viral detection methods increased yield of
detectable episodes. PIV infections were more likely to be transiently
asymptomatic than RSV, MPV, or ﬂu. Asymptomatic shedding of
PIV provides a possible explanation of why infection control pro-
grams emphasizing symptoms are highly effective against RSV but
often not versus other viruses such as PIV. These data may guide
implementation of more effective diagnosis and infection control
strategies.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT ACUTE LEU-
KAEMIA IN CR1 AND CR2 WITH A NOVEL MYELOABLATIVE CONDI-
TIONING REGIMEN INCORPORATING DAILY INTRAVENOUS BUSULFAN,
FLUDARABINE, 400 cGy TOTAL BODY IRRADIATION AND LOW-DOSE
ANTITHYMOCYTE GLOBULIN
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Larratt, L.1, Turner, R.1, Storek, J.1, Quinlan, D.1, Geddes, M.1,
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